NKG2A silencing in effector cells to improve effectivity of cell based therapeutics by unknown
BioMed Central
Page 1 of 1
(page number not for citation purposes)
Cell Communication and Signaling
Open AccessMeeting abstract
NKG2A silencing in effector cells to improve effectivity of cell based 
therapeutics
C Figueiredo*, J Zenk, B Eiz-Vesper, R Blasczyk and A Seltsam
Address: Institute for Transfusion Medicine, Hannover Medical School, Hannover, Germany
* Corresponding author    
The heterodimeric NKG2A/CD94 receptor delivers an
inhibitory signal upon recognition of HLA-E molecules.
In several studies it has been demonstrated that signalling
via NKG2A/CD94 receptor significantly reduces T or NK
cell cytotoxic activity and cytokine production. In hemat-
opoietic stem cell transplantation, expression of NKG2A
on NK and T cells has been shown to compromise the
graft-versus-leukemia effect. In addition, NKG2A was
shown to inhibit tumor-specific T cell responses. In this
study, we developed a RNAi-based approach to perma-
nently silence the expression of NKG2A molecules on NK
and T-cells. The functional relevance of NKG2A silencing
for the cytotoxic potential of genetically engineered NK
and T-cells was evaluated.
NKG2A+ cells were isolated from fresh PBMCs. Lentiviral
vectors were designed to express short hairpin RNA
sequences (shRNA) targeting NKG2A transcripts. The
level of NKG2A suppression was measured by flow cytom-
etry and real-time RT-PCR. The effect of NKG2A receptor
silencing on the cytolytic potential of NK and T cells was
evaluated in cytotoxicity assays using K562 and B-LCL
cells as targets. In addition, granzyme B mRNA transcript
levels were detected by real-time RT-PCR.
The transduction of inducible RNAi cassettes containing
the sequences for shRNAs targeting NKG2A caused a
reduction of protein expression by up to 80% in NK and
T cells. In cytotoxicity assays, it was demonstrated that
NKG2A silencing was effective to enhance NK and CD8+ T
cell lysis by up to 40%. In comparison with unmodified
cells, granzyme B transcript levels were upregulated by up
to 12-fold in NKG2A silenced cells after target exposure.
Expression of NKG2A-specific shRNA did not affect the
expression of the activating markers NKp44 on NK cells
and CD25 on T cells.
Our data suggest that RNAi-mediated silencing of NKG2A
in effector cells could improve the effectivity of cell-based
immunotherapeutics and might be of particular interest
in an autologous approach.
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